Barbara Wirostko to Speak at 5th Ocular Diseases Conference Mar 21-22, 2013

Printer-friendly versionPDF version

Barbara Wirostko, Chief Scientific Officer and Co-Founder of Jade Therapeutics and Clinical Adjunct Associate Professor of Ophthalmology at University of Utah To Give a Featured Presentation at the 5th Ocular Diseases & Drug Development Conference (March 21-22, 2013 in San Francisco, CA)

San Francisco, CA, USA., January 10, 2013 - (PressReleasePoint) - Barbara Wirostko, Chief Scientific Officer and Co-Founder of Jade Therapeutics and Clinical Adjunct Associate Professor of Ophthalmology at University of Utah will give a featured presentation at GTC’s 5th Ocular Diseases and Drug Development Conference to be held in San Francisco, CA on March 21-22, 2013. Dr. Wirostko is also a chairperson and session moderator for the event.
 
Dr. Barbara Wirostko is a board certified Ophthalmologist and maintains an academic research and clinical affiliation with the University of Utah, Moran Eye Center, as a Clinical Adjunct Associate Professor in Ophthalmology.  Prior to co-founding Jade Therapeutics, she was Chief Medical Officer of Altheos, a biotech company developing a ROCK inhibitor for glaucoma. She serves on the Grant Review Working Group for CIRM, California Institute for Regenerative Medicine and is on the editorial board of Acta Ophthalmologic and World Journal of Ophthalmology.  Dr. Wirostko consults for several companies including SKS, Merck, Macuclear and iVeena. Prior to Altheos, she was Senior Medical Director within the Clinical Development and Medical Affairs division at Pfizer in NY. She oversaw the development of pipeline glaucoma strategy and global medical / clinical programs for Xalabrands. She was the team lead for a successful Phase 3 regulatory filing to the European regulatory agency (EMA) for a pediatric glaucoma indication. 
 
GTC’s 5th Ocular Diseases and Drug Development Conference promotes the discovery of ocular disease drug development by bringing together leading scientists, researchers, and experts to discuss and collaborate on the latest research and discovery, safety assessment, and drugs in development for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, DME, uveitis and other eye diseases. The last annual conference was well attended by key R&D delegates GSK, Pfizer, B&L, Allergan and Alcon, and this year’s conference promises to be even bigger and better.
 
For more information, please visit www.gtcbio.com